Novartis will partner with Dunad Therapeutics to develop oral covalent and protein degrading small molecule drugs for undisclosed diseases, through a collaboration that could generate more than $1.3 billion for the year-old developer of next-generation targeted protein degradation therapies—and revive a presence in the segment for the pharma giant.
Dunad, which emerged from stealth mode in March, has agreed to apply its fully tunable and selective platform to generate drugs focusing on up to four drug targets to be agreed upon with Novartis.
